Operating
Charges for acquired in-process research and development
Johnson & Johnson Charges for acquired in-process research and development remained flat by 0.0% to $27.25M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 94.1%, from $460.25M to $27.25M.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2021
Last reportedQ4 2025Feb 11, 2026
How to read this metric
High charges indicate aggressive acquisition strategies to bolster the innovation pipeline.
Detailed definition
These are accounting charges related to the acquisition of in-process research and development projects through business...
Peer comparison
Standard in pharmaceutical and biotech sectors where external innovation is a key growth driver.
Metric ID:
operating_research_and_development_expenseHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $483.00M | $1.84B | $109.00M |
| YoY Change | — | — | — | +281.2% | -94.1% |
Range$0.00 – $1.84B
Avg YoY Growth+93.5%
Median YoY Growth+93.5%
Charges for acquired in-process research and development at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's charges for acquired in-process research and development?
- Johnson & Johnson (JNJ) reported charges for acquired in-process research and development of $27.25M in Q4 2025.
- How has Johnson & Johnson's charges for acquired in-process research and development changed year-over-year?
- Johnson & Johnson's charges for acquired in-process research and development decreased by 94.1% year-over-year, from $460.25M to $27.25M.
- What does charges for acquired in-process research and development mean?
- The cost of R&D projects acquired from other companies that are expensed immediately upon purchase.